GlassScriptPhysician profile
Amro Balki
NPI 1922237593
$465,036.61
in general payments reported to CMS, 2019-2025
55 companies · $256K in 2025
The $256K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $17K · 2021: $10K · 2022: $19K · 2023: $26K · 2024: $106K · 2025: $256K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $252K · Consulting Fee: $61K · Travel and Lodging: $42K · Food and Beverage: $32K · Honoraria: $1,800 · Education: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $252,143.50 |
| Consulting Fee | $60,515.95 |
| Travel and Lodging | $41,927.26 |
| Food and Beverage | $31,569.01 |
| Honoraria | $1,800.00 |
| Education | $395.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $143,385.95 | 2019-2025 | Evenity, Uplizna, Otezla |
| Janssen Biotech, INC. | $112,875.88 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $57,871.29 | 2019-2025 | |
| Ucb, INC. | $49,100.35 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $46,476.37 | 2019-2025 | |
| Abbvie INC. | $13,595.42 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Sobi, INC | $8,453.65 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $6,172.38 | 2021-2025 | Saphnelo |
| Regeneron Pharmaceuticals, INC. | $4,664.35 | 2019-2020 | |
| Medexus Pharma, INC. | $3,874.27 | 2019 | |
| Horizon Therapeutics Plc | $3,143.24 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $2,057.70 | 2019-2025 | Taltz, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $2,032.65 | 2019-2025 | Benlysta, Nucala |
| Janssen Global Services, LLC | $2,000.00 | 2021 | |
| Pfizer INC. | $1,912.41 | 2019-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $969.46 | 2019-2025 | Ofev, Cyltezo |
| Mallinckrodt Hospital Products INC. | $912.23 | 2020-2025 | Acthar |
| Depuy Synthes Sales INC. | $555.27 | 2019-2024 | Monovisc |
| Radius Health, INC. | $501.88 | 2019-2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $467.49 | 2022-2025 | Purified Cortrophin Gel, Sovuna |
| E.R. Squibb & Sons, L.L.C. | $341.26 | 2019-2025 | Orencia |
| Bioventus LLC | $341.23 | 2019-2025 | Durolane, Xcell, Durolane |
| Janssen Scientific Affairs, LLC | $285.08 | 2019-2021 | |
| Pacira Therapeutics, INC. | $247.24 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $238.03 | 2023-2025 | Idacio, Adalimumab-Aacf |
| Antares Pharma, INC. | $216.27 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $212.23 | 2019-2024 | Strensiq |
| Hikma Pharmaceuticals USA | $203.65 | 2019-2023 | Mitigare |
| Mallinckrodt Enterprises LLC | $194.71 | 2019 | |
| Celgene Corporation | $187.63 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $185.11 | 2021-2023 | Arcalyst |
| Aurinia Pharma U.S., INC. | $125.00 | 2024 | Lupkynis |
| Alvogen INC | $116.03 | 2023-2025 | Teriparatide |
| Fidia Pharma USA INC. | $103.17 | 2024 | Hymovis, Hyalgan, Triluron |
| Genentech USA, INC. | $102.30 | 2020-2025 | Actemra |
| Sanofi-Aventis U.S. LLC | $99.21 | 2019-2020 | |
| Octapharma USA, INC. | $96.15 | 2023-2024 | Octagam Immune Globulin (Human), Panzyga |
| Scilex Pharmaceuticals INC. | $83.07 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $76.01 | 2024 | Arcalyst |
| Teva Pharmaceuticals USA, INC. | $70.00 | 2023 | |
| Redhill Biopharma INC. | $60.44 | 2020-2021 | |
| Sandoz INC. | $57.03 | 2023-2025 | Hyrimoz, Jubbonti |
| Kyowa Kirin, INC. | $47.90 | 2024 | Crysvita |
| Celltrion USA INC. | $47.44 | 2023 | Yuflyma |
| Ibsa Pharma INC. | $43.06 | 2022-2024 | Tirosint, Licart |
| Vertiflex, INC. | $35.96 | 2019 | |
| Zyla Life Sciences, INC. | $30.31 | 2019 | |
| Organon LLC | $27.70 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $25.42 | 2021 | |
| Kedrion Biopharma, INC. | $24.63 | 2025 | Rhogam Ultra-Filtered Plus, Albuked, Kedrab |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.12 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $21.44 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.28 | 2023 | Quviviq |
| Tonix Medicines, INC. | $16.97 | 2025 | Tonmya |
| Shionogi INC | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amro Balki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.